Flavonoid-based therapies in the early management of neurodegenerative diseases

Adv Nutr. 2015 Jan 15;6(1):64-72. doi: 10.3945/an.114.007500. Print 2015 Jan.

Abstract

During the past several years, there has been enormous progress in the understanding of the causative factors that initiate neuronal damage in various neurodegenerative diseases, including Alzheimer disease, Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington disease. Preventing neuronal damage and neuronal death will have a huge clinical benefit. However, despite major advances in causative factors that trigger these neurodegenerative diseases, to date there have been no therapies available that benefit patients who suffer from these diseases. Because most neurodegenerative diseases are late-onset and remain asymptomatic for most of the phases, the therapies initiated in advanced stages of the disease have limited value to patients. It may be possible to prevent or halt the disease progression to a great extent if therapies start at the initial stage of the disease. Such therapies may restore neuronal function by reducing or even eliminating the primary stressor. Flavonoids are key compounds for the development of a new generation of therapeutic agents that are clinically effective in treating neurodegenerative diseases. Regular consumption of flavonoids has been associated with a reduced risk of neurodegenerative diseases. In addition to their antioxidant properties, these polyphenolic compounds exhibit neuroprotective properties by their interaction with cellular signaling pathways followed by transcription and translation that mediate cell function under both normal and pathologic conditions. This review focuses on human intervention studies as well as animal studies on the role of various flavonoids in the prevention of neurodegenerative diseases.

Keywords: antioxidant; bioactive compounds; cellular signaling; cognitive functions; flavonoids; mitochondria; neurodegenerative diseases; neuroprotection; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Amyotrophic Lateral Sclerosis / drug therapy*
  • Animals
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Brain / drug effects*
  • Flavonoids / pharmacology
  • Flavonoids / therapeutic use*
  • Humans
  • Huntington Disease / drug therapy*
  • Multiple Sclerosis / drug therapy*
  • Neurodegenerative Diseases / drug therapy
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Parkinson Disease / drug therapy*
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use

Substances

  • Antioxidants
  • Flavonoids
  • Neuroprotective Agents
  • Plant Extracts